- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT04176198
Studie perorálního TP-3654 u pacientů s myelofibrózou
Fáze 1/2, otevřená, eskalace dávky, bezpečnost, farmakokinetická a farmakodynamická studie perorálního TP-3654 u pacientů se středním nebo vysokým rizikem primární nebo sekundární myelofibrózy
This study is a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of nuvisertib (TP-3654) in patients with intermediate or high-risk primary or secondary MF.
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Detailní popis
Arm 1 will enroll patients who have been previously treated and failed on a JAK inhibitor or ineligible to receive treatment with a JAK inhibitor.
Arm 2 will enroll patients who are on a stable dose of ruxolitinib, but who have either lost response or had a suboptimal or plateau in response.
Arm 3 will enroll patients who have been previously treated with a JAK inhibitor (except momelotinib)
Typ studie
Zápis (Odhadovaný)
Fáze
- Fáze 2
- Fáze 1
Kontakty a umístění
Studijní kontakt
- Jméno: Reyna Bishop
- Telefonní číslo: 617-674-6800
- E-mail: reyna.bishop@us.sumitomo-pharma.com
Studijní záloha kontaktů
- Jméno: Jordan Simpson
- E-mail: jordan.simpson@us.sumitomo-pharma.com
Studijní místa
-
-
-
Adelaide, Austrálie
- Nábor
- Icon Cancer Centre (Ashford Cancer Centre Research)
-
Kontakt:
- Stanley Cheung, MD
- E-mail: Stanley.Cheung@icon.team
-
-
South Australia
-
Adelaide, South Australia, Austrálie
- Nábor
- Royal Adelaide Hospital
-
Kontakt:
- Christine Hoare
- E-mail: christine.hoare@sa.gov.au
-
-
Victoria
-
Box Hill, Victoria, Austrálie
- Nábor
- Eastern Health Box Hill Hospital
-
Kontakt:
- SMPA Investigative Site
-
Clayton, Victoria, Austrálie
- Nábor
- Monash University
-
Kontakt:
- SMPA Investigative Site
-
Fitzroy, Victoria, Austrálie
- Nábor
- St Vincent's Hospital Melbourne
-
Kontakt:
- SMPA Investigative Site
-
Melbourne, Victoria, Austrálie
- Nábor
- Peter McCallum Center
-
Kontakt:
- SMPA Investigative Site
-
Richmond, Victoria, Austrálie
- Nábor
- Epworth Healthcare
-
Kontakt:
- SMPA Investigative Site
-
-
-
-
-
Antwerp, Belgie, 2020
- Nábor
- ZNA Cadix
-
Kontakt:
- SMPA Investigative Site
-
Antwerp, Belgie, 2030
- Nábor
- ZNA Middelheim
-
Kontakt:
- SMPA Investigative Site
-
Ghent, Belgie, 9000
- Nábor
- Universitair Ziekenhuis Gent
-
Kontakt:
- SMPA Investigative Site
-
Liège, Belgie, 4000
- Nábor
- CHU de Liege
-
Kontakt:
- SMPA Investigative Site
-
-
Vlaams-Brabant
-
Leuven, Vlaams-Brabant, Belgie, 3000
- Nábor
- University Hospitals Leuven
-
Kontakt:
- SMPA Investigative Site
-
-
-
-
-
Amiens, Francie, 80054
- Nábor
- Centre Hospitalier Universitaire D'Amiens
-
Kontakt:
- SMPA Investigative Site
-
Angers, Francie, 9000
- Nábor
- CHU Angers
-
Kontakt:
- SMPA Investigative Site
-
Lyon, Francie, 69495
- Nábor
- Centre Hospitalier Lyon Sud
-
Kontakt:
- SMPA Investigative Site
-
Nice, Francie, 06200
- Nábor
- Hospitalier Universitaire (CHU) de Nice - Hopital de l'Archet
-
Kontakt:
- SMPA Investigative Site
-
Nîmes, Francie, 30029
- Nábor
- Institut de cancerologie du Gard
-
Kontakt:
- SMPA Investigative Site
-
Nîmes, Francie
- Nábor
- Institut de cancerologie du Gard
-
Kontakt:
- SMPA Investigative Site
-
Paris, Francie, 75010
- Nábor
- Hospital Saint Louis
-
Kontakt:
- SMPA Investigative Site
-
Poitiers, Francie, 86021
- Nábor
- University Hospital of Poitiers
-
Kontakt:
- SMPA Investigative Site
-
Villejuif, Francie, 94805
- Nábor
- Institut Gustave Roussy
-
Kontakt:
- SMPA Investigative Site
-
-
-
-
-
Alessandria, Itálie, 15121
- Nábor
- Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo
-
Kontakt:
- SMPA Investigative Site
-
Aviano, Itálie, 33081
- Nábor
- Istituto Nazionale Tumori, IRCCS Centro di Riferimento Oncologico di Aviano
-
Bologna, Itálie, 40138
- Nábor
- IRCCS Azienda Ospedaliero -Universitaria Di Bologna - Dipartimento Malattie Oncologiche ed Ematologiche - UO Ematologia
-
Kontakt:
- SMPA Investigative Site
-
Brescia, Itálie
- Nábor
- ASST - Spedali Civili di Brescia
-
Kontakt:
- SMPA Investigative Site
-
Meldola, Itálie, 47014
- Nábor
- IRCCS istituto Romagnolo per lo studio dei tumori "Dino Amadori"
-
Kontakt:
- SMPA Investigative Site
-
Milan, Itálie, 20122
- Nábor
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
-
Kontakt:
- SMPA Investigative Site
-
Torino, Itálie, 10126
- Nábor
- Azienda Ospedaliera Universitaria Citta' Della Salute E della Scienza di Torino
-
Kontakt:
- SMPA Investigative Site
-
-
-
-
-
Aichi, Japonsko
- Nábor
- Aichi Medical University Hospital
-
Kontakt:
- Akiyoshi Takami
- Telefonní číslo: 0561-62-3311
- E-mail: takami.akiyoshi.490@mail.aichi-med-u.ac.jp
-
Aomori, Japonsko
- Nábor
- Aomori Prefectural Central Hospital
-
Kontakt:
- Tomoaki Akagi, MD
- Telefonní číslo: 017-726-8111
- E-mail: tomakagi@med.pref.aomori.jp
-
Chiba, Japonsko
- Nábor
- National Cancer Center Hospital East
-
Kontakt:
- Junichiro Yuda, MD
- Telefonní číslo: 04-7133-1111
- E-mail: jyuda@east.ncc.go.jp
-
Fukuoka, Japonsko
- Nábor
- Kyushu University Hospital
-
Kontakt:
- Takuji Yamauchi, MD
- Telefonní číslo: 092-641-1151
- E-mail: yamauchi.takuji.355@m.kyushu-u.ac.jp
-
Hokkaido, Japonsko
- Nábor
- Hokkaido University Hospital
-
Kontakt:
- Takanori Teshima, MD
- Telefonní číslo: 011-716-1161
- E-mail: teshima@med.hokudai.ac.jp
-
Kamakura, Japonsko, 247-8533
- Nábor
- Shonan Kamakura General Hospital
-
Kontakt:
- Tomiteru Togano, MD
- Telefonní číslo: 0467-46-1717
- E-mail: t_togano@shonankamakura.or.jp
-
Miyazaki, Japonsko
- Nábor
- University of Miyazaki Hospital
-
Kontakt:
- Kazuya Shimoda, MD
- Telefonní číslo: 0985-85-1510
- E-mail: kshimoda@med.miyazaki-u.ac.jp
-
Okayama, Japonsko
- Nábor
- Okayama University Hospital
-
Kontakt:
- Noboru Asada, MD
- Telefonní číslo: 086-223-7151
- E-mail: nasada@okayama-u.ac.jp
-
Osaka, Japonsko
- Nábor
- The University of Osaka Hospital
-
Kontakt:
- Michiko Ichii, MD
- Telefonní číslo: 06-6879-5111
-
Saitama, Japonsko
- Dokončeno
- Saitama Medical Center
-
Sendai, Japonsko
- Nábor
- Tohoku University Hospital
-
Kontakt:
- Noriko Fukuhara, MD
- Telefonní číslo: 022-717-7000
-
Shizuoka, Japonsko
- Dokončeno
- Shizuoka Cancer Center
-
Tokyo, Japonsko, 160-0023
- Nábor
- Tokyo Medical University Hospital
-
Kontakt:
- Daigo Akahane, MD
- Telefonní číslo: 03-3342-6111
- E-mail: dakahane@tokyo-med.ac.jp
-
Tokyo, Japonsko
- Nábor
- Juntendo University Hospital
-
Kontakt:
- Shuichi Shirane, MD
- Telefonní číslo: 03-3813-3111
- E-mail: sshirane@juntendo.ac.jp
-
Tokyo, Japonsko, 179-0072
- Nábor
- Nerima Hikarigaoka Hospital
-
Kontakt:
- Akihiko Gotoh, MD
- Telefonní číslo: 03-3979-3611
- E-mail: akgotou@juntendo.ac.jp
-
Tsu, Japonsko
- Nábor
- Mie University Hospital
-
Kontakt:
- Yuka Sugimoto, MD
- Telefonní číslo: 059-232-1111
- E-mail: yuka2@clin.medic.mie-u.ac.jp
-
-
-
-
Alberta
-
Calgary, Alberta, Kanada, T2N 1N4
- Nábor
- University of Calgary
-
Kontakt:
- Sonia Cerquozzi
- E-mail: sonia.cerquozzi@albertahealthservices.ca
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V6T 1Z3
- Nábor
- University of British Columbia
-
Kontakt:
- SMPA Investigative Site
-
Vancouver, British Columbia, Kanada, V6T 1Z3
- Nábor
- St. Paul's Hospital Hematology/Oncology Research
-
Kontakt:
- Kelsi Sorensen
- Telefonní číslo: 604-682-2344
- E-mail: ksorensen1@providencehealth.bc
-
-
Ontario
-
Hamilton, Ontario, Kanada, L8V 5C2
- Nábor
- Juravinski Cancer Center
-
Kontakt:
- SMPA Investigative Site
-
Toronto, Ontario, Kanada, M5G 2M9
- Nábor
- Princess Margaret Cancer Center
-
Kontakt:
- Vikas Gupta
- E-mail: vikas.gupta@uhn.ca
-
-
Quebec
-
Montreal, Quebec, Kanada, H3T 1E2
- Nábor
- Jewish General Hospital
-
Kontakt:
- SMPA Investigative Site
-
-
-
-
-
Halle, Německo
- Nábor
- Universitätsmedizin Halle
-
Kontakt:
- SMPA Investigative Site
-
Lübeck, Německo
- Nábor
- Universitätsklinikum Schleswig-Holstein
-
Kontakt:
- SMPA Investigative Site
-
-
-
-
-
Lincoln, Spojené království
- Nábor
- Lincoln County Hospital
-
Kontakt:
- SMPA Investigative Site
-
Lincoln, Spojené království
- Nábor
- United Lincolnshire Hospitals NHS Trust - Pilgrim Hospital
-
Kontakt:
- SMPA Investigative Site
-
London, Spojené království
- Nábor
- University College London Hospital's NHS foundation Trust
-
Kontakt:
- SMPA Investigative Site
-
Oxford, Spojené království
- Nábor
- Oxford University Hospitals NHS Foundation
-
Kontakt:
- SMPA Investigative Site
-
-
-
-
Alabama
-
Birmingham, Alabama, Spojené státy, 35294
- Nábor
- University of Alabama
-
Kontakt:
- Tiffany Hill
- Telefonní číslo: 205-934-9591
-
-
Arizona
-
Tucson, Arizona, Spojené státy, 85724
- Nábor
- The University of Arizona Cancer Center
-
Kontakt:
- Audrey Johnson
- Telefonní číslo: 520-694-9084
- E-mail: audieejayy@arizona.edu
-
-
California
-
Duarte, California, Spojené státy, 91010
- Nábor
- City of Hope
-
Kontakt:
- Michelle Velasquez
- Telefonní číslo: 626-218-3524
- E-mail: mvelaszuez@coh.org
-
Los Angeles, California, Spojené státy, 90033
- Nábor
- University of Southern California
-
Kontakt:
- Shirley Sian
- Telefonní číslo: 323-865-0456
- E-mail: sian_s@med.usc.edu
-
Newport Beach, California, Spojené státy, 92663
- Nábor
- Hoag Family Cancer Institute
-
Kontakt:
- Patrice Jones
- Telefonní číslo: 949-764-5501
- E-mail: patrice.jones@hoag.org
-
-
Colorado
-
Denver, Colorado, Spojené státy, 80218
- Nábor
- Blood Cancer Center
-
Kontakt:
- Brooke Rhodes
- E-mail: Brookerhodes@sarahcannon.com
-
-
Connecticut
-
New Haven, Connecticut, Spojené státy, 06510
- Nábor
- Yale School of Medicine
-
Kontakt:
- Farah Fasihuddin
- Telefonní číslo: 203-494-4610
- E-mail: farah.fasihuddin@yale.edu
-
-
Florida
-
Gainesville, Florida, Spojené státy, 32608
- Dokončeno
- University of Florida Health Shands Cancer Hospital
-
Miami, Florida, Spojené státy, 33136
- Nábor
- University of Miami
-
Kontakt:
- Alessia Zoso
- Telefonní číslo: 305-243-0327
- E-mail: azoso@miami.edu
-
Miami, Florida, Spojené státy, 33176
- Nábor
- Baptist Health - Miami Cancer Institute
-
Kontakt:
- Firas El Chaer, MD
- Telefonní číslo: 786-596-2000
- E-mail: firas.elchaer@baptisthealth.net
-
-
Georgia
-
Atlanta, Georgia, Spojené státy, 30322
- Nábor
- Emory University
-
Kontakt:
- Suzanne Scott
- Telefonní číslo: 404-778-4334
- E-mail: suzanne.e.scott@emory.edu
-
-
Illinois
-
Chicago, Illinois, Spojené státy, 60637
- Nábor
- University of Chicago
-
Kontakt:
- Howie Weiner
- E-mail: HWeiner@bsd.uchicago.edu
-
-
Maryland
-
Baltimore, Maryland, Spojené státy, 21201
- Nábor
- University of Maryland
-
Kontakt:
- Maria Baer, MD
- Telefonní číslo: 410-328-8708
- E-mail: mbaer@umm.edu
-
-
Massachusetts
-
Boston, Massachusetts, Spojené státy, 02114
- Nábor
- Massachusetts General Hospital
-
Kontakt:
- Gabriela Hobbs, MD
- E-mail: ghobbs@mgb.org
-
-
Michigan
-
Ann Arbor, Michigan, Spojené státy, 48109
- Nábor
- University of Michigan
-
Kontakt:
- Kelsey Bolin
- Telefonní číslo: 734-936-2193
- E-mail: kntillma@med.umich.edu
-
-
Minnesota
-
Minneapolis, Minnesota, Spojené státy, 55455
- Nábor
- University of Minnesota
-
Kontakt:
- Naveen Premnath, MD
- E-mail: premn007@umn.edu
-
-
Missouri
-
St Louis, Missouri, Spojené státy, 63110
- Nábor
- Washington University of Medicine
-
Kontakt:
- Nicole Gaudin
- Telefonní číslo: 314-747-7960
- E-mail: nrgaudin@wustl.edu
-
-
New Jersey
-
Hackensack, New Jersey, Spojené státy, 07601
- Nábor
- John Theurer Cancer Center at Hackensack University Medical Center
-
Kontakt:
- Parita Patel
- Telefonní číslo: 551-996-5900
- E-mail: parita.patel@hmhn.org
-
-
New York
-
Buffalo, New York, Spojené státy, 14263
- Dokončeno
- Roswell Park Comprehensive Cancer Center
-
New York, New York, Spojené státy, 10065
- Nábor
- Memorial Sloan Kettering Cancer Center
-
Kontakt:
- Tamanna Haque, MD
- E-mail: haquet1@mskcc.org
-
New York, New York, Spojené státy, 10029
- Nábor
- Icahn School of Medicine at Mount Sinai
-
Kontakt:
- Gabriela Bello
- E-mail: gabriela.bello@mssm.edu
-
New York, New York, Spojené státy, 10065
- Nábor
- Weill Cornell Medical Center
-
Kontakt:
- Penina Steward
- Telefonní číslo: 212-746-1858
- E-mail: pes4006@med.cornell.edu
-
The Bronx, New York, Spojené státy, 10461
- Nábor
- Montefiore Cancer Center
-
Kontakt:
- Olivia Orellano
- E-mail: oorellano@montefiore.org
-
-
North Carolina
-
Durham, North Carolina, Spojené státy, 27710
- Nábor
- Duke Cancer Institute
-
Kontakt:
- Ben Dosan
- E-mail: benjamin.dosan@duke.edu
-
-
Ohio
-
Columbus, Ohio, Spojené státy, 43210
- Nábor
- Ohio State University
-
Kontakt:
- Molly Brandenburg
- Telefonní číslo: 614-366-7951
- E-mail: Molly.Brandenburg@osumc.edu
-
-
South Carolina
-
Charleston, South Carolina, Spojené státy, 29425
- Nábor
- Medical University of South Carolina
-
Kontakt:
- Jared Hortman
- E-mail: hortman@musc.edu
-
-
Tennessee
-
Nashville, Tennessee, Spojené státy, 37232
- Nábor
- Vanderbilt University
-
Kontakt:
- SMPA Investigative Site
-
Nashville, Tennessee, Spojené státy, 37203
- Nábor
- Tri-Star Centennial Medical Center
-
Kontakt:
- Brooke Rhodes
- E-mail: brooke.rhodes@sarahcannon.com
-
-
Texas
-
Houston, Texas, Spojené státy, 77054
- Nábor
- MD Anderson Cancer Center
-
Kontakt:
- Kurt Schroeder
- Telefonní číslo: 713-745-2232
- E-mail: kdschroe@mdanderson.org
-
-
Utah
-
Salt Lake City, Utah, Spojené státy, 84112
- Nábor
- Huntsman Cancer Institute
-
Kontakt:
- Nicole Fisher
- Telefonní číslo: 801-587-7000
- E-mail: nicole.fisher@hci.utah.edu
-
-
Virginia
-
Charlottesville, Virginia, Spojené státy, 22903
- Nábor
- University of Virginia Cancer Center
-
Kontakt:
- Avani Hopkins
- Telefonní číslo: 434-243-8108
- E-mail: AJH7JQE@uvahealth.org
-
-
Washington
-
Seattle, Washington, Spojené státy, 98109
- Nábor
- University of Washington - Fred Hutchinson Cancer Center
-
Kontakt:
- Anna Halpern
- E-mail: halpern2@uw.edu
-
-
-
-
-
Barcelona, Španělsko
- Nábor
- Hospital Universitario y Politecnico La Fe
-
Kontakt:
- SMPA Investigative Site
-
Barcelona, Španělsko
- Nábor
- Institut Catala d'Oncologia
-
Kontakt:
- SMPA Investigative Site
-
Salamanca, Španělsko
- Nábor
- Hospital Universitario de Salamanca
-
Kontakt:
- SMPA Investigative Site
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Patients must meet all of the following inclusion criteria to be eligible:
Nuvisertib (TP-3654) Monotherapy Arm:
- Confirmed pathological diagnosis of primary myelofibrosis (PMF) or post-PV-MF/post-ET- MF and intermediate or high-risk primary or secondary MF
- Previously treated with JAK inhibitor(s) and is intolerant, resistant, refractory or has lost response to the JAK inhibitor(s) or is ineligible to be treated with JAK inhibitor
- Fulfill the following clinical laboratory parameters:
- Platelet count ≥ 25 x 10^9 /L, without assistance of growth factors or platelet transfusions
- ANC ≥ 1 x 10^9/L without assistance of granulocyte growth factors
- Peripheral blood blast count < 5%
- ECOG performance status ≤ 1
- Life expectancy ≥ 6 months
- Adequate renal function
- Adequate hepatic function
- Adequate coagulation function
- Splenomegaly (spleen volume of ≥ 450 cm3 by MRI or CT scan) within 2 weeks prior to Cycle 1 Day 1.
- Dose escalation: At least 2 symptoms measurable (score ≥ 1) using the MF-SAF
- Dose expansion: At least 2 symptoms measurable with each score of ≥ 3 or a total average score of ≥ 10 per MFSAF
Nuvisertib (TP-3654) + Ruxolitinib Arm:
- Confirmed pathological diagnosis of PMF or post-PV-MF/post ET- MF and intermediate or high-risk primary or secondary MF
- On ruxolitinib treatment for ≥ 6 months, and on a stable dose of ruxolitinib (5 to 25 mg BID) for ≥ 8 weeks prior to the first dose of nuvisertib, but has either lost response or had a suboptimal or plateau in response
- Fulfills the following clinical laboratory parameters:
- Platelet count ≥ 50 × 10^9/L (without assistance of growth factors or platelet transfusions)
- ANC ≥ 1 × 109/L without assistance of granulocyte growth factors
- Peripheral blood blast count < 5% at screening
- Adequate renal function
- Adequate hepatic function
- Adequate coagulation function
- Splenomegaly (spleen volume of ≥ 450 cm3 by MRI/CT scan) within 2 weeks prior to Cycle 1 Day 1
- At least 2 symptoms measurable with each score ≥ 3 or a total average score of ≥ 10 per MFSAF v4.0
- ECOG performance status ≤ 1
- Life expectancy ≥ 6 months
Nuvisertib (TP-3654) + Momelotinib Arm
- Confirmed pathological diagnosis of PMF or post-PV-MF/post ET-MF and intermediate or high-risk primary or secondary MF
- Previously treated with an approved JAK inhibitor (except momelotinib) for PMF or Post-PV/ET MF for ≥ 12 weeks, or ≥ 4 weeks if JAK inhibitor therapy was complicated by a transfusion requirement of ≥ 4 units of red blood cells in 8 weeks, or Grade 3/4 AEs of thrombocytopenia, anemia, or hematoma
- Fulfills the following clinical laboratory parameters:
- Anemic, defined as Hb <10 g/dL or requiring RBC transfusion at baseline
- Platelet count ≥ 50 × 109/L (without assistance of growth factors or platelet transfusions)
- ANC ≥ 1 × 109/L without assistance of granulocyte growth factors
- Peripheral blood blast count < 5% at screening
- Adequate renal function
- Adequate hepatic function
- Adequate coagulation function
- Splenomegaly (spleen volume of ≥ 450 cm3 by MRI/CT scan) within 2 weeks prior to Cycle 1 Day 1
- At least 2 symptoms measurable with each score of ≥ 3 or a total average score of ≥ 10 per MFSAF v4.0
- ECOG performance status ≤ 1
- Life expectancy ≥ 6 months
Patients meeting any one of these exclusion criteria will be prohibited from participating in this study:
Nuvisertib (TP-3654) Monotherapy Arm:
- Received previous systemic antineoplastic therapy or any experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1. Hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1).
- Major surgery within 4 weeks prior to Cycle 1 Day 1 and/or not recovered adequately from from surgery prior to first dose.
- Splenic irradiation within 6 months prior to Screening or prior splenectomy.
- Prior allogeneic stem cell transplant within the last 6 months.
- Eligible for allogeneic bone marrow or stem cell transplantation.
- Unresolved Grade ≥ 2 non-hematological toxicity related to prior treatment
- History of symptomatic congestive heart failure, or myocardial infarction, or uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1; left ventricular ejection fraction (LVEF) < 45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1.
- Corrected QT interval > 480msec.
- Prior or concurrent malignancy that could interfere with the investigational regime.
- Known history of chronic liver disease, e.g. portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc.
- Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic antimicrobial within 1 week prior to Cycle 1 Day 1.
- Chronic active or acute viral hepatitis A, B, or C infection (testing for hepatitis B and C are required)
- Exhibited allergic reactions or sensitivity to nuvisertib, or similar compound.
- Medical condition or GI tract surgery that could impair absorption or result in short bowel syndrome with diarrhea.
- Systemic steroid therapy (>10 mg daily prednisone or equivalent) within 1 week prior to the first dose of study treatment (note: topical, inhaled, nasal, and ophthalmic steroids are not prohibited).
- Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or thalassemia, or severe GI bleeding.
- Pregnant or breastfeeding
- Currently receiving any other investigational agent.
Nuvisertib (TP-3654) + Ruxolitinib Arm:
- Received previous systemic antineoplastic therapy (other than ruxolitinib) or any other experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1 (Note: Prior treatment with nuvisertib is not allowed. Hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1).
- Received systemic steroid therapy (>10 mg daily prednisone or equivalent) within 1 week prior to Cycle 1 Day 1 (Note: Topical, inhaled, nasal, and ophthalmic steroids are not prohibited)
- Known allergic reactions or sensitivity to nuvisertib, or similar compound.
- Splenic irradiation within 6 months prior to Screening or prior splenectomy
- Prior allogeneic stem cell transplant within the last 6 months (Note: Patients who have relapsed after 6 months post-transplant and do not have active GVHD are eligible).
- Eligible for allogeneic bone marrow or stem cell transplantation (Note: Patients who are not willing to undergo transplantation or for whom a suitable donor is not available are considered as transplant ineligible.)
- Major surgery within 4 weeks prior to Cycle 1 Day 1 and/or have not recovered adequately prior to first dose.
- Active, uncontrolled bacterial, viral, or fungal infections, requiring parenteral antimicrobial within 1 week prior to Cycle 1 Day 1
- Chronic active or acute viral hepatitis A, B, or C infection (testing for hepatitis B and C are required)
- Known history of chronic liver disease (eg, portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc) (Note: Abnormal liver morphology at baseline imaging may require additional testing, as needed).
- Unresolved Grade ≥ 2 non-hematological adverse events related to prior treatment (stable Grade 2 conditions may be permitted in consultation with the Sponsor)
- History of myocardial infarction or symptomatic congestive heart failure or uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1; LVEF <45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1
- Corrected QTcF of > 480 msec
- Prior or concurrent malignancy that could interfere with the safety or efficacy assessment of the study intervention
- History of a medical condition or GI tract surgery that could impair absorption or could result in short bowel syndrome with diarrhea
- Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or thalassemia, or severe GI bleeding
- Pregnant or breastfeeding
Nuvisertib (TP-3654) + Momelotinib Arm:
- Received previous systemic antineoplastic therapy or any experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1 (Notes: Prior treatment with momelotinib or nuvisertib is not allowed; in patients with ongoing JAK inhibitor therapy, ie, ruxolitinib, at screening, JAK inhibitor therapy must be tapered over a period of at least 1 week. Patients on a low dose of ruxolitinib (eg, 5 mg QD) may have a reduced taper period or no taper; hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1).
- Received systemic steroid therapy (>10 mg daily prednisone or equivalent) within 1 week prior to Cycle 1 Day 1 (Note: Topical, inhaled, nasal, and ophthalmic steroids are not prohibited).
- Known allergic reactions or sensitivity to nuvisertib, momelotinib, or any structurally similar drug, or to any component of the formulations of either study intervention
- Splenic irradiation within 6 months prior to screening or prior splenectomy
- Prior allogenic stem cell transplant within the last 6 months (Note: Patients who have relapsed after 6 months post-transplant and do not have active GVHD are eligible).
- Eligible for allogeneic bone marrow or stem cell transplantation (Note: Patients who are not willing to undergo transplantation or for whom a suitable donor is not available are considered as transplant ineligible).
- Major surgery within 4 weeks prior to Cycle 1 Day 1 and/or have not recovered adequately from surgery prior to first dose.
- Active, uncontrolled bacterial, viral, or fungal infections, requiring parenteral antimicrobial within 1 week prior to Cycle 1 Day 1
- Chronic active or acute viral hepatitis A, B, or C infection (testing for hepatitis B and C are required)
- Known history of chronic liver disease (eg, portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc) (Note: Abnormal liver morphology at baseline imaging may require additional testing, as needed)
- Unresolved Grade ≥ 2 non-hematological adverse events related to prior treatment (stable Grade 2 conditions may be permitted in consultation with the Sponsor)
- Presence of Grade ≥ 2 peripheral neuropathy
- History of myocardial infarction or symptomatic congestive heart failure or uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1; LVEF < 45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1
- Corrected QTcF of > 480 msec
- Prior or concurrent malignancy that could interfere with the safety or efficacy assessment of the study intervention
- History of a medical condition or GI tract surgery that could impair absorption or could result in short bowel syndrome with diarrhea
- Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or thalassemia, or severe GI bleeding
- Pregnant or breastfeeding
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Nerandomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Rameno 1: nuvisertib (TP-3654)
|
Oral PIM Inhibitor
Ostatní jména:
|
|
Experimentální: Rameno 2: nuvisertib (TP-3654) přidaný k ruxolitinibu
|
Oral PIM Inhibitor
Ostatní jména:
Oral JAK inhibitor
Ostatní jména:
|
|
Experimentální: Rameno 3: nuvisertib (TP-3654) v kombinaci s momelotinibem
|
Oral PIM Inhibitor
Ostatní jména:
Oral JAK inhibitor
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Determine the incidence of dose-limiting toxicities (DLTs)
Časové okno: 28 days
|
Number of participants with DLTs |
28 days
|
|
Determine the incidence of treatment emergent adverse events
Časové okno: From start of treatment to end of study
|
Number of participants with Treatment Emergent Adverse Events and Serious Adverse Events |
From start of treatment to end of study
|
|
Assess patients for any evidence of preliminary activity by determining the number of patients with ≥ 35% spleen volume reduction (SVR35)
Časové okno: From start of treatment to end of study
|
Number of participants with ≥ 35% spleen volume reduction (SVR35) |
From start of treatment to end of study
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Number of participants achieving objective response by IWG-MRT response criteria
Časové okno: From start of treatment to end of study
|
Number of participants achieving complete remission, partial remission, clinical improvement, progressive disease and stable disease. |
From start of treatment to end of study
|
|
Number of participants who have ≥ 25% spleen volume reduction
Časové okno: Every 12 weeks from cycle 1 day 1 through cycle 19 day 1, and then every 24 weeks therafter during treatment.
|
Number of participants who have ≥ 25% spleen volume reduction compared to baseline |
Every 12 weeks from cycle 1 day 1 through cycle 19 day 1, and then every 24 weeks therafter during treatment.
|
|
Number of participants with ≥ 50% improvement in total symptom score (TSS50) at week 24
Časové okno: 24 weeks
|
Number of participants who have ≥ 50% total symptom score reduction by MFSAF compared to baseline after 24 weeks of treatment. |
24 weeks
|
|
Determine the change in Patient Global Impression of Change (PGIC) at week 24 through end of study.
Časové okno: After 24 weeks of treatment to end of study
|
Change in PGIC score |
After 24 weeks of treatment to end of study
|
|
Determine the incidence of QT interval changes
Časové okno: 25 hours
|
Changes in QT interval and heart rhythm |
25 hours
|
|
Establish the half-life (t½) of nuvisertib monotherapy, in combination with ruxolitinib, and in combination with momelotinib
Časové okno: 24 hours
|
The estimate of time for the nuvisertib concentration or amount to be reduced by half |
24 hours
|
|
Establish the Area under the plasma concentration versus time curve (AUC) of nuvisertib monotherapy, in combination with ruxolitinib, and in combination with momelotinib
Časové okno: 24 hours
|
The amount of drug exposure over 24 hours period after administration |
24 hours
|
|
Establish the Peak Plasma Concentration (Cmax) of nuvisertib monotherapy, in combination with ruxolitinib, and in combination with momelotinib
Časové okno: 24 hours
|
The maximum nuvisertib concentration after administration |
24 hours
|
|
Establish the Time of Maximum concentration observed (tmax) of nuvisertib monotherapy, in combination with ruxolitinib, and in combination with momelotinib
Časové okno: 24 hours
|
The time to reach maximum nuvisertib concentration |
24 hours
|
Další výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Počet pacientů se snížením fibrózy kostní dřeně
Časové okno: Každých 24 týdnů do konce studia
|
Každých 24 týdnů do konce studia
|
|
|
Ramena s kombinací Nuvisertibu: Zhodnoťte zvýšení hemoglobinu ≥ 1,5 nebo ≥ 2 g/dl oproti výchozí hodnotě
Časové okno: Od začátku léčby do konce studie
|
Od začátku léčby do konce studie
|
|
|
Kombinovaná ramena nuvisertibu: Zhodnoťte stav nezávislosti na transfuzi červených krvinek nebo jakoukoli změnu požadavku
Časové okno: Od začátku léčby do konce studie
|
Od začátku léčby do konce studie
|
|
|
Monoterapie NuviSertib: Změny počtu destiček v průběhu času u pacientů s počtem základních destiček <100 x 10^9/l
Časové okno: Od začátku léčby po ukončení studia
|
Od začátku léčby po ukončení studia
|
|
|
Study potential pharmacodynamic (PD) markers of nuvisertib
Časové okno: 12 months
|
Evaluate exploratory biomarkers, including change in protein phosphorylation and inflammatory cytokines, in peripheral blood samples and bone marrow biopsy samples. |
12 months
|
|
Establish overall survival
Časové okno: From start of treatment to end of study
|
The time interval from treatment start date to date of death from any cause |
From start of treatment to end of study
|
Spolupracovníci a vyšetřovatelé
Sponzor
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- BBI-TP-3654-102
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .